厄多司坦辅助治疗慢性阻塞性肺疾病急性加重期的效果分析  

Efficacy analysis of erdostine in the treatment of acute exacerbation of chronic obstructive pulmonary disease

作　　者：凌媛 陈列 林丽娜 LING Yuan;CHEN Lie;LIN Li'na(Department of Respiratory Medicine,Shenyang 242 Hospital,Shenyang,Liaoning,110034,China)

机构地区：[1]沈阳二四二医院呼吸内科,辽宁沈阳110034

出　　处：《当代医学》2022年第28期97-100,共4页Contemporary Medicine

摘　　要：目的探究厄多司坦辅助治疗慢性阻塞性肺疾病急性加重期(AECOPD)的效果。方法选取2018年3月至2019年4月本院收治的90例AECOPD患者作为研究对象,按照随机数字表法分为对照组和观察组,各45例。对照组采用多索茶碱治疗,观察组在对照组基础上采用厄多司坦辅助治疗。比较两组临床疗效、肺功能[用力肺活量(FVC)、第1秒用力呼吸容积(FEV_(1))、第1秒用力呼气容积与用力肺活量的比值(FEV_(1)/FVC)、动脉血氧分压(PaO_(2))、动脉血二氧化碳分压(PaCO_(2))]水平、抗氧化能力[丙二醇(MDA)、超氧化物歧化酶(SOD)、谷胱甘肽(GSH)]及不良反应发生情况。结果观察组治疗总有效率为93.33%,高于对照组的77.78%,差异有统计学意义(P<0.05)。治疗前,两组FVC、FEV_(1)、FEV_(1)/FVC、PaO_(2)、MDA、SOD、GSH水平比较差异无统计学意义;治疗后,两组FVC、FEV_(1)、FEV_(1)/FVC、PaO_(2)、SOD、GSH水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组PaCO_(2)、MDA水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论厄多司坦辅助治疗AECOPD疗效确切,能改善患者肺功能,提高抗氧化能力,值得临床推广应用。Objective To investigate the effect of erdocatestan in the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods A total of 90 patients with AECOPD admitted to our hospital from March 2018 to April 2019 were selected as research subjects,and 45 cases were divided into control group and observation group according to the random number table method.The control group was treated with doxofylline,and the observation group was treated with erdostestane in addition to the control group.The clinical efficacy,lung function(forced vital capacity[FVC],forced expiratory volume in one second[FEV_(1)],forced expiratory volume in one second to forced vital capacity[FEV_(1)/FVC],arterial partial pressure of oxygen[PaO_(2)],arterial blood carbon dioxide partial pressure[PaCO_(2)]),antioxidant capacity(maleic dialdehyde[MDA],superoxide dismutase[SOD],glutathione[GSH])and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 93.33%,which was higher than 77.78%in the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in the levels of FVC,FEV_(1),FEV_(1)/FVC,PaO_(2),MDA,SOD,and GSH between the two groups;after treatment,the levels of FVC,FEV_(1),FEV_(1)/FVC,PaO_(2),SOD and GSH in the two groups were higher than those before treatment,and the observation group was higher than that in the control group,with a statistically significant difference(P<0.05),and the levels of PaCO_(2) and MDA in the two groups were lower than before treatment,and the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion Erdostestan adjuvant treatment of AECOPD has a definite efficacy,can improve lung function and antioxidant capacity,and is worthy of clinical application.

关 键 词：厄多司坦 慢性阻塞性肺疾病 多索茶碱 抗氧化能力 

分 类 号：R563.9[医药卫生—呼吸系统]